TABLE 2.

Univariate analysis of demographic characteristics and clinical pathological characteristics of cancer subjects with and without sarcoid-like granuloma

Variable	Cancer only	Cancer and granuloma	p-value	OR (95 CI)
Subjects n	134	46	–	–
Age at cancer diagnosis	57.9±14.3	58.3±12.96	0.860	–
Average years of follow-up	6.0±6.4	5.5±5.1	0.615
Male	53 (39.5)	24 (52.1)	0.137	1.67 (0.85–3.27)
European-American	56 (41.8)	16 (34.8)	0.403	0.74 (0.37–1.49)
Hispanic	57 (42.5)	12 (26.1)	0.050	0.48 (0.23–1)
African American	17 (12.7)	8 (17.4)	0.428	1.45 (0.58–3.62)
Asian	2 (1.4)	8 (17.4)	0.001	13.90 (2.83–68.2)
Smokers	70 (52.2)	17 (36.9)	0.087	0.55 (0.27–1.09)
Average years of smoking	30.92	36.4	0.243	–
Alive <2 years	20 (46.5)	12 (80)	0.033	4.6 (1.13–18.65)
Alive <4 years	40 (50.6)	20 (80)	0.013	3.9 (1.33–11.42)
Alive <6 years	48 (51.1)	30 (85.7)	0.001	5.75 (2.05–16.1)
Alive <10 years	57 (51.3)	35 (85.4)	<0.0001	5.53 (2.15–14.18)
Alive >10 years	16 (69.6)	5 (100)	–	–
Bladder cancer	7 (5.2)	3 (6.5)	0.741	1.27 (0.31–5.11)
Breast cancer	37 (27.7)	8 (17.4)	0.171	0.55 (0.24–1.3)
Colon cancer	7 (5.2)	5 (10.9)	0.195	2.21 (0.67–7.35)
Lung cancer	30 (22.4)	6 (13)	0.177	0.52 (0.2–1.34)
Lymphoma	15 (11.2)	6 (13)	0.736	1.19 (0.43–3.28)
Melanoma	18 (13.4)	5 (10.9)	0.654	0.79 (0.27–2.25)
Pancreatic cancer	4 (3)	3 (6.5)	0.296	2.27 (0.49–10.54)
RCC	8 (6)	1 (2.2)	0.329	0.35 (0.04–2.88)
Sarcoma	2 (1.5)	3 (6.5)	0.100	4.61 (0.75–28.48)
Prostate cancer	6 (4.4)	6 (13)	0.055	3.2 (0.97–10.47)
Cancer stage 4	72 (57.6)	6 (13)	<0.0001	0.17 (0.07–0.44)
Surgery	86 (67.2)	26 (56.5)	0.798	0.91 (0.43–1.92)
Radiotherapy	69 (53.9)	13 (28.3)	0.020	0.41 (0.2–0.87)
Chemotherapy	90 (70.3)	20 (43.5)	0.020	0.42 (0.20–0.87)
mAb therapy	55 (43.0)	8 (17.4)	0.011	0.33 (0.14–0.78)

Data are presented as mean±sd or n (%), unless otherwise stated. RCC: renal cell carcinoma; mAb: monoclonal antibody therapy.